Navigation Links
Nuvelo Announces Publication of Preclinical Study Results,Demonstrating the Potential of NTB-A as a New Target for Leukemia,and Lymphomas

als.

    (1) Byrd, J.C., Stilgenbauer, S. & Flinn, I.W. (2004) Chronic lymphocytic

        leukemia. Hematology (American Society of Hematology Education

        Program), 1, 163-183.

    (2) Kokhaei, P., Palma, M., Mellstedt, H. & Choudhury, A. (2005) Biology

        and treatment of chronic lymphocytic leukemia. Annals of Oncology,

        16(Suppl. 2), ii113-123.

    (3) Kuriakose, P. (2005) Targeted therapy for hematologic malignancies.

        Cancer Control, 12, 82-90.

    (4) Ortin, M. (2005) Immunotherapy of hematological malignancies: what is

        new? Annals of Oncology, 16(Suppl. 2), ii53-62.

About Nuvelo's Cancer Antibody Program

Nuvelo's cancer antibody pipeline includes advanced targets in leukemia and lymphoma, and earlier-stage solid tumor targets in colon, lung and breast cancers. Nuvelo has developed monoclonal antibodies specific to these targets and is testing them in animal models. These models test the ability of antibodies to shrink human tumor tissue growing in immunodeficient mice (xenografts). Nuvelo is continuing to evaluate leading monoclonal antibodies in more advanced preclinical studies, and those that are sufficiently validated in animal models may move into to clinical trials.

About Nuvelo

Nuvelo, Inc. is dedicated to improving the lives of patients through the discovery, development and commercialization of novel drugs for acute cardiovascular and cancer therapy. Nuvelo's development pipeline includes three acute cardiovascular programs: alfimeprase, a direct-acting fibrinolytic for the treatment of thrombotic-related disorders; rNAPc2, an anticoagulant that inhibits the factor VIIa and tissue factor protease complex that completed Phase 2 clinical development in acute coronary syndromes; and preclinical candidate NU172, a direct thrombin inhibitor for use as a short-acting anticoagulant during medical or surgical procedures. Nuvelo is also advancing an emerging oncology
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Nuvelo Announces Presentations on rNAPc2 and NU172 at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. Nuvelo Announces Publication of Phase 2 rNAPc2 Study Results in Journal of American College of Cardiology
3. Nuvelo Announces Publication of NU206 Study Results in Gastroenterology
4. Nuvelo Announces Presentation on NU206 at 2007 American Association for Cancer Research Annual Meeting
5. Nuvelo Announces Presentation on rNAPc2 at American College of Cardiology 56th Annual Scientific Session
6. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
7. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
9. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
10. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
11. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
Post Your Comments:
(Date:8/27/2008)...ionally Recognized Pediatric Heart Center at The C...s for Community to Complete Range of Care and ...Recruited Pediatric Cardiology Team Treats Every H...ewswire/ -- The Children,s Hospital at,Montefiore ...c heart,transplantation to the Bronx, following th...
(Date:8/26/2008)...SALEM, Ore., Aug. 26 /- The Oregon To...ity Care Customer Service Training Program,(Q Care...gon Q Care is a training program created to suppor...anced employee education. By emphasizing,the impor...ll equip,employees with tools and resources to bet...
(Date:8/26/2008)...INDIANAPOLIS, Aug. 26 /- Semafore Pha...Seventh International Congress on Targeted,Therapi...al antiangiogenic,activity of vascular-targeted PI... VEGF and Bv8 signaling., PI3K is part of a very ...as been shown to play a major role in cancer. Stud...
(Date:8/26/2008)...Study finds most patients can drive safely six wee...Aug. 26 /PRNewswire-USNewswire/ -- Six weeks follo...e so low that they are able to,get back behind the...gust,2008 issue of The Journal of Bone and Joint S...ergency brake time response in patients who underw...
Breaking Medicine Technology:Pediatric Heart Transplants at Montefiore Approved by NY State Department of Health 2Pediatric Heart Transplants at Montefiore Approved by NY State Department of Health 3Pediatric Heart Transplants at Montefiore Approved by NY State Department of Health 4Oregon Tourism Commission Unveils New Online Customer Service Training Program 2SF1126, Semafore's PI3 Kinase Inhibitor, Found to Block Angiogenic Signaling From Both VEGF and Bv8 in Multiple Cell Lines 2SF1126, Semafore's PI3 Kinase Inhibitor, Found to Block Angiogenic Signaling From Both VEGF and Bv8 in Multiple Cell Lines 3Braking After Bunion Surgery 2Braking After Bunion Surgery 3Arena Pharmaceuticals Announces Positive Phase 1b Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis 2601 1Arena Pharmaceuticals Announces Positive Phase 1b Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis 2601 2Arena Pharmaceuticals Announces Positive Phase 1b Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis 2601 3Arena Pharmaceuticals Announces Positive Phase 1b Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis 2601 4Arena Pharmaceuticals Announces Positive Phase 1b Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis 2601 5MDS Commences Arbitration against AECL over Cancelled MAPLE Project and Files 241 6 Billion Court Claim against AECL and the Government of Canada 23553 1MDS Commences Arbitration against AECL over Cancelled MAPLE Project and Files 241 6 Billion Court Claim against AECL and the Government of Canada 23553 2MDS Commences Arbitration against AECL over Cancelled MAPLE Project and Files 241 6 Billion Court Claim against AECL and the Government of Canada 23553 3CellCyte Genetics Retains InCap Group to Advise on Business Strategy and Financing 6439 1CellCyte Genetics Retains InCap Group to Advise on Business Strategy and Financing 6439 2CellCyte Genetics Retains InCap Group to Advise on Business Strategy and Financing 6439 3CellCyte Genetics Retains InCap Group to Advise on Business Strategy and Financing 6439 4Economic Stimulus Act Can Improve Medical Equipment Purchasing Power 23549 1Economic Stimulus Act Can Improve Medical Equipment Purchasing Power 23549 2
(Date:8/29/2008)...esults of a 10-year study published in the August ...found that magnesium sulfate administered to women...he risk of cerebral palsy by 50 percent. The Benef...) trial was conducted in 18 centers in the U.S., i...renatal intervention ever found to reduce the inst...
(Date:8/29/2008)... http://www.aronowitzmd.com [Los An...espected experience in plastic surgery procedures ...consideration may be necessary for these patients,...e an established specialty of procedures for after...es, CA (PRWEB) August 29, 2008 -- Bariatric surger...
(Date:8/28/2008)...ues increase 138% versus Q2 2007 - Nine new Cen...RNewswire-FirstCall/ - CRH Medical Corporation,(CR... three and six months,ended June 30, 2008 (all fig...ths ended June 30, 2008 increased 138% to $1,653,8...7. Revenue for the six months ended June,30, 2008 ...
(Date:8/28/2008)...ion will be based in the Northeast region with mor...xt year, HARRISBURG, Pa., Aug. 28 /PRNewswire-USN...ity has hired a Patient Safety Liaison for the,Nor...eport to the,Pennsylvania Patient Safety Reporting...ylvania citizens., "Last year in focus groups wit...
Breaking Medicine News(10 mins):Health News:National study shows magensium sulfate reduces risk of cerebral palsy in premature births 2Health News:Dr. Joel Aronowitz, Specialist in Los Angeles Body Lift, Announces Plastic Surgery Options After Bariatric Surgery Weight Loss 2Health News:Dr. Joel Aronowitz, Specialist in Los Angeles Body Lift, Announces Plastic Surgery Options After Bariatric Surgery Weight Loss 3Health News:Dr. Joel Aronowitz, Specialist in Los Angeles Body Lift, Announces Plastic Surgery Options After Bariatric Surgery Weight Loss 4Health News:CRH Medical reports Q2 2008 results 2Health News:CRH Medical reports Q2 2008 results 3Health News:CRH Medical reports Q2 2008 results 4Health News:CRH Medical reports Q2 2008 results 5Health News:Pennsylvania Patient Safety Authority Hires Patient Safety Liaison to Help Healthcare Facilities Implement Guidance 2Health News:Pennsylvania Patient Safety Authority Hires Patient Safety Liaison to Help Healthcare Facilities Implement Guidance 3
...ty Massey Cancer Center have discovered a process ...cules containing platinum, which causes HIV and ca...the researchers to develop new drugs to fight HIV ...argeting proteins known as zinc fingers. In the M...
...at funds for wheelchair service from NHS has not r...ildren are losing out their hope due to lack of a ...wheelchair with most basic parts, was given due to...sh Me Around!’, highlights. Thus it calls for Gove...
...n (NBA) have entered into a partnership to support.... // The campaign, 'Unite for Children, Unite aga.../AIDS on children as well as impeding further spre...e know that our sport, indeed all sports, has an e...
...hetamine-like stimulant has a calming effect on ch...er (ADHD) // . A new study undertaken on rats, se...ly used to treat ADHD, appears to work by tweaking...acted by any stimuli from the outside world. The s...
Other Medicine News:Health News:New Research May Be Useful for Developing Drugs for HIV and Cancer 2Health News:Ritalin Could Help In Focussing The Mind 2
...s a national reference laboratory and a worldwide ...opment. ARUP offers an extensive test menu of high...d anatomic pathology. Owned by the University of U...half of the nation's university teaching hospitals...
...s a national reference laboratory and a worldwide ...opment. ARUP offers an extensive test menu of high...d anatomic pathology. Owned by the University of U...half of the nation's university teaching hospitals...
...s a national reference laboratory and a worldwide ...opment. ARUP offers an extensive test menu of high...d anatomic pathology. Owned by the University of U...half of the nation's university teaching hospitals...
...s a national reference laboratory and a worldwide ...opment. ARUP offers an extensive test menu of high...d anatomic pathology. Owned by the University of U...half of the nation's university teaching hospitals...
Medicine Products: